ClinicalTrials.gg
TerminatedNCT05696392MORPHEUSUpdated Dec 19, 2025Results posted

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

A Phase 4 interventional study of ruxolitinib cream in Atopic Dermatitis, sponsored by Incyte Corporation. Terminated at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by Incyte Corporation · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was terminated due to lack of enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ruxolitinib in Dermatitis, Atopic — 2 open to participants now, 3 under way, 1 of them phase 3. ruxolitinib · Dermatitis, Atopic.

Enrollment
12th of 15
47 · median 77
Started
2023
the only one that year
Phase 4
3 of 15
2 open now
Registered
11th of 15
by date
Lead sponsor
13 of 15
Incyte Corporation

Among the 15 studies testing ruxolitinib in Dermatitis, Atopic, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 3 in phase 4, and was the 11th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 15 studies testing ruxolitinib in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ruxolitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • ruoltitinib
  • atopic dermatitis
  • sleep distubance
  • itch
  • Opzelura
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has clinically confirmed diagnosis of active AD according to Hanifin and Rajka (1980) criteria.
  • Has at least a 2-year history of AD (information obtained from medical chart, participant's physician, or directly from the participant).
  • Has an overall BSA affected by AD of 3%-20% (excluding scalp) at the screening and baseline visits.
  • Has an IGA score ≥ 2 at the screening and baseline visits.
  • Has an Itch NRS score ≥ 4 at the screening and baseline visits.
  • Willing to complete the once-daily Itch NRS (24-hour recall period) entries at approximately the same time each day during the study.
  • Agrees to maintain a regular sleep schedule during the study period.
  • Willing and able to follow required study procedures for measuring sleep for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Currently using a wearable or other device for monitoring sleep patterns and unwilling to discontinue its use during the study.
  • Currently has a schedule that includes nighttime work shifts.
  • Has had significant flares or unstable course in AD (ie, condition worsened significantly or required significant change in medications, as per medical judgment) in the previous 4 weeks before screening (information obtained from medical chart, participant's physician, or directly from the participant).
  • Has received any ultraviolet B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to the screening period.
  • Has had psoralen plus ultraviolet A treatment within 4 weeks prior to the screening period.
  • Has received a nonbiological product or device within 4 weeks prior to the screening period, or is currently enrolled in another investigational drug study.
  • Has received treatment with JAK inhibitors (systemic or topical) within 4 weeks prior to the screening period.
  • Has had prior treatment with a JAK inhibitor that was discontinued for safety reasons or tolerance problems.
  • Has a known or suspected allergy to ruxolitinib or any component of the study drug.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Treatment Group: Ruxolitinib

    ruxolitinib cream 1.5% will be applied twice daily (BID) as a thin film.

    Drug: ruxolitinib cream

Interventions

  • ruxolitinib cream 1.5% will be applied twice daily as a thin film

    Also known as: INCB018424

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Sleep Time (TST) as Measured by Ōura Ring Wearable Device at Week 8

    TST is the total amount of time spent during a planned sleep episode. Decreased TST is indicative of increased sleep disturbance. Baseline TST was the average hours of sleep within the last 7 nights prior to Visit 1. The Week 8 TST was the average hours of sleep within the last 7 nights prior to Visit 3/Week 8. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Week 8

Secondary outcomes

  1. Change From Baseline in PROMIS Sleep Disturbance - Short Form 8b Score (24-hour Recall) at Week 8

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 8b is a validated instrument used to measure the severity of sleep disturbance. The PROMIS score includes 8 items, each of which asks the participant to rate the severity of their sleep disturbance on a daily basis on a severity scale of 1 to 5. The PROMIS total score is calculated as the sum of the 8 items and ranges from 8 to 40. A higher PROMIS score indicates more severe sleep disturbance. The baseline score was the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 1 and their response at Visit 1. Week 8 scores comprised the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 3 and their response at Visit 3. The average was not valid and was set to missing if scores were missing on 4 or more days. Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; Week 8

07

Results

Posted Dec 19, 2025
Limitations and caveats
The study was terminated early due to challenges with enrollment. Sample size was limited due to a high number of screen failures and important Protocol deviations.

Participant flow

Participant flow — Overall Study
MilestoneRuxolitinib 1.5% Cream BID
Started47
Completed42
Not completed5
Withdrew: Lost to follow-up3
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange From Baseline in Total Sleep Time (TST) as Measured by Ōura Ring Wearable Device at Week 8

TST is the total amount of time spent during a planned sleep episode. Decreased TST is indicative of increased sleep disturbance. Baseline TST was the average hours of sleep within the last 7 nights prior to Visit 1. The Week 8 TST was the average hours of sleep within the last 7 nights prior to Visit 3/Week 8. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Week 8
Reported as:
Mean · hours
Change From Baseline in Total Sleep Time (TST) as Measured by Ōura Ring Wearable Device at Week 8
hoursRuxolitinib 1.5% Cream BID
Baseline5.69 ± 0.956
Change from baseline at Week 80.09 ± 1.145
Statistical analysis
  • Ruxolitinib 1.5% Cream BID · paired t-test · p = 0.8357
SecondaryChange From Baseline in PROMIS Sleep Disturbance - Short Form 8b Score (24-hour Recall) at Week 8

The Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 8b is a validated instrument used to measure the severity of sleep disturbance. The PROMIS score includes 8 items, each of which asks the participant to rate the severity of their sleep disturbance on a daily basis on a severity scale of 1 to 5. The PROMIS total score is calculated as the sum of the 8 items and ranges from 8 to 40. A higher PROMIS score indicates more severe sleep disturbance. The baseline score was the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 1 and their response at Visit 1. Week 8 scores comprised the 7-day average of nonmissing scores for the 6 days preceding a participant's Visit 3 and their response at Visit 3. The average was not valid and was set to missing if scores were missing on 4 or more days. Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; Week 8
Reported as:
Mean · scores on a scale
Change From Baseline in PROMIS Sleep Disturbance - Short Form 8b Score (24-hour Recall) at Week 8
scores on a scaleRuxolitinib 1.5% Cream BID
Baseline27.58 ± 4.955
Change from baseline at Week 8-7.47 ± 7.802
Statistical analysis
  • Ruxolitinib 1.5% Cream BID · paired t-test · p = 0.0001

Adverse events

Collected over up to 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib 1.5% Cream BID0/47 (0%)0/47 (0%)7/47 (14.9%)
Most frequent other events
Most frequent other events
EventRuxolitinib 1.5% Cream BID
Upper respiratory tract infectionInfections and infestations2/47
Application site painGeneral disorders1/47
NasopharyngitisInfections and infestations1/47
FallInjury, poisoning and procedural complications1/47
Muscle strainInjury, poisoning and procedural complications1/47
Blood creatine phosphokinase increasedInvestigations1/47
Joint swellingMusculoskeletal and connective tissue disorders1/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ruxolitinib 1.5% Cream BID
Mean40.9 ± 16.43
Sex: Female, Male
Sex: Female, Male(Participants)Ruxolitinib 1.5% Cream BID
Female27
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ruxolitinib 1.5% Cream BID
Hispanic or Latino7
Not Hispanic or Latino39
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ruxolitinib 1.5% Cream BID
Asian8
Black or African American16
Not Reported1
Captured as "Other" in Database1
White21
08

Study locations

30 sites
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Gw Training Center
    Washington D.C., District of Columbia 20037, United States
  • Skin Care Research, Llc
    Boca Raton, Florida 33486, United States
  • Driven Research Llc
    Coral Gables, Florida 33134, United States
  • University of Florida Health Dermatology-Springhill
    Gainesville, Florida 32606, United States
  • Skin Care Research, Llc Scr Hollywood
    Hollywood, Florida 33021, United States
  • Ciocca Dermatology Pa
    Miami, Florida 33173, United States
  • Trueblue Clinical Research
    Tampa, Florida 33609, United States
  • Dermatology Specialists Research Indiana
    Clarksville, Indiana 47129, United States
  • Dawes Fretzin Clinical Research Group Llc
    Indianapolis, Indiana 46250, United States
  • Skin Sciences Pllc
    Louisville, Kentucky 40217, United States
  • Beth Israel Deaconess Medical Center (Bidmc)
    Boston, Massachusetts 02215, United States
  • Northeast Dermatology Associates
    Methuen, Massachusetts 01844, United States
  • Essential Dermatology
    Natick, Massachusetts 01760, United States
  • Washington University School of Medicine Dermatology
    St Louis, Missouri 63110, United States
  • Suny Downstate Health Sciences University
    Brooklyn, New York 11203, United States
  • Empire Dermatology
    East Syracuse, New York 13057, United States
  • Sadick Dermatology
    New York, New York 10075, United States
  • Skin Search of Rochester
    Rochester, New York 14623, United States
  • Ohio Pediatric Research Association
    Dayton, Ohio 45414, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Knight Cancer Institute At Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Arlington Research Center
    Arlington, Texas 76011, United States
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
  • Pi Coor Clinical Research Llc
    Burke, Virginia 22015, United States
  • Clinical Research Partners Llc
    Richmond, Virginia 23226, United States
  • Dermatology Specialists of Spokane
    Spokane, Washington 99202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jan 2025, 22 months.

Results were first posted in Dec 2025, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2023
First posted
Jan 25, 2023
StartActual
Mar 16, 2023
Primary completionActual
Jan 22, 2025
CompletionActual
Jan 22, 2025
Results first posted
Dec 19, 2025
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05696392
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jan 25, 2023
Start date
Mar 16, 2023
Primary completion
Jan 22, 2025
Completion
Jan 22, 2025
Results posted
Dec 19, 2025
Last update
Dec 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion